A double blind randomized controlled trial on baloxavir marboxil and flufenamic acid combination for severe hospitalized influenza infection

Professor Hung, Fan Ngai Ivan   (Principal Investigator (PI))

Dr Zhang Jinxia   (Co-Investigator)

Professor To Kelvin Kai Wang   (Co-Investigator)

Dr Chan Kwok Hung   (Co-Investigator)

Professor Yuen Kwok Yung   (Co-Investigator)

48

2020-10-01

1161819

A double blind randomized controlled trial on baloxavir marboxil and flufenamic acid combination for severe hospitalized influenza infection

baloxavir, flufenamic-acid, hospitalized, influenza, severe

Infection/Parasitology

Biology and Medicine (M)

17119820

General Research Fund (GRF)

2020

On-going

1 A combination of baloxavir marboxil and FFA will reduce mortality in patients with severe influenza infection compared with baloxavir marboxil alone. 2 A combination of baloxavir marboxil and FFA will suppress viral load in patients with severe influenza infection compared with baloxavir marboxil alone. 3 A combination of baloxavir marboxil and FFA will suppress cytokine dysregulation in patients with severe influenza infection compared with baloxavir marboxil alone. 4 A combination of baloxavir marboxil and FFA will suppress cytokine dysregulation in patients with severe influenza infection compared with baloxavir marboxil alone. 5 A combination of baloxavir marboxil and FFA will suppress cytokine dysregulation in patients with severe influenza infection compared with baloxavir marboxil alone. 6 To assess the safety of a double combination of baloxavir marboxil and FFA for treatment of acute complicated influenza infection. 7 To assess the clinical efficacy of a double combination of baloxavir marboxil and FFA for treatment of acute complicated influenza infection.